Well Referenced

Tag: nausea

Intravenous Vitamin C Administration Improves Quality of Life in Breast Cancer Patients During Chemo-/Radiotherapy and Aftercare: Results of a Retrospective, Multicentre, Epidemiological Cohort Study in Germany

This 2011 retrospective multicenter cohort study evaluated the safety and efficacy of intravenous vitamin C (IVC) administration in 125 women with breast cancer (UICC stages IIa–IIIb) during the first postoperative year. Fifty-three patients received 7.5 g IVC weekly alongside standard chemo-/radiotherapy, while 72 served as controls. The IVC group experienced

Read More »
June 26, 2025 No Comments

Impact of Intravenous Vitamin C Administration in Reducing Severity of Symptoms in Breast Cancer Patients During Treatment

This single-center, single-blind, randomized controlled trial conducted in Pakistan assessed the effects of intravenous vitamin C (IVC) on symptom severity in 350 breast cancer patients (stages IIA–IIIb) undergoing standard treatment. Participants were randomized to receive either 25g/week of IVC or placebo over four weeks. The IVC group showed statistically significant

Read More »
June 26, 2025 No Comments

Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer’s dementia

This randomized controlled trial investigated the effects of acetyl-L-carnitine (ALC) on cognitive function in patients with Alzheimer’s-type dementia. While no statistically significant differences were observed between the ALC and placebo groups, trends suggested potential benefits in short-term memory, as measured by the Names Learning Test and Digit Recall Test. Additionally,

Read More »
June 26, 2025 No Comments

An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder

Bremelanotide, a melanocortin receptor agonist, has shown statistically significant improvements in sexual desire and reduced distress related to hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as a subcutaneous injection on an as-needed basis, it provides an on-demand treatment option. However, the overall clinical benefit is modest, and nausea

Read More »
June 26, 2025 No Comments

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

This randomized controlled trial evaluated the safety, pharmacokinetics, and pharmacodynamics of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction (ED). The study found that PT-141 elicited significant erectile responses at doses greater than 7 mg, with erections occurring approximately 30 minutes post-administration. Pharmacokinetic

Read More »
June 26, 2025 No Comments

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II

This randomized controlled trial evaluated the effects of Melanotan II, a melanocortin receptor agonist, on penile erection and sexual desire in men with psychogenic and organic erectile dysfunction (ED). Among 20 participants, 85% experienced spontaneous penile erections without sexual stimulation, and 68% reported increased sexual desire after Melanotan II administration,

Read More »
June 26, 2025 No Comments